Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2019

Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

(1) , (1) , (2) , (3) , (4) , (5) , (6, 7, 8) , (9) , (10) , (11) , (12) , (13, 7, 8) , (14) , , (15) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Aurore Perrot
  • Fonction : Auteur
  • PersonId : 769019
  • IdRef : 139420215
Jean-Pierre Marolleau
  • Fonction : Auteur
  • PersonId : 887235
  • IdRef : 06981676X
Laure Devlamynck
  • Fonction : Auteur

Dates et versions

hal-03605012 , version 1 (10-03-2022)

Identifiants

Citer

Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, Xavier Leleu, Thierry Facon, et al.. Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03). Blood, 2019, 134 (1), ⟨10.1182/blood-2019-123184⟩. ⟨hal-03605012⟩
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More